Abstract 3029
Background
About half of ESS do not harbor a JAZF1 or YWHAE fusion and other rearrangements have already been reported. With the aim to provide a comprehensive description of the molecular landscape of endometrial stromal sarcomas (ESS), we investigated by RNA-sequencing a series of tumors diagnosed as ESS based on the morphology but negative for JAZF1 and/or YWHAE in FISH experiments.
Methods
This study was performed between September 2017 and December 2018 as a Centre Léon Bérard monocentric retrospective translational research program on tumor samples from an investigational cohort of 43 ESS patients. For clustering analyses, we used a control cohort composed of 19 patient samples of BCOR-rearranged sarcomas (n = 8), low-grade ESS with JAZF1-SUZ12 fusion (n = 5), high-grade ESS carrying a BCOR internal tandem duplication (n = 1), uterine leiomyoma (n = 2) and uterine leiomyosarcomas (n = 3). RNA sequencing was performed from FFPE material in all cases using TruSeq RNA Access Library Prep Kit (Illumina®).
Results
A chromosomal rearrangement was identified in 74% of the cases (n = 32). We identified biologically homogeneous groups of tumors such as the JAZF1-fused (to PHF1 and SYNGAP1) and the BCOR-rearranged (BCOR-ITD, ZC3H7B-BCOR, CREBBP-BCOR). Using a clustering approach on transcriptomic data, tumors were divided in 3 subgroups: one mainly composed of BCOR-rearranged ESS (n = 7), one mainly composed of JAZF1-fused ESS (n = 14) and one composed of various molecular subtypes (n = 22). This 3 subgroups display significantly different survivals (Log-rank test, p = 0.004). Five cases which harbored a YWAHE-NUTM2B fusions clustered separately: 3 cases in the group of indolent tumors (JAZF1-fused ESS) and 2 cases in the group of aggressive tumors (BCOR-rearranged sarcomas). Of note, those 2 cases harbored also a single nucleotide variant, one on BCOR and one on BCORL1. Results of RNA-seq and clustering analysis have allowed a better classification in 6 cases.
Conclusions
This is the largest series of RNAseq performed in a very rare subtype of tumors: ESS. We report new and recurrent molecular variants of ESS including previously unreported fusions. RNA-sequencing may support the diagnosis of ESS and help a better classification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
InterSARC grants.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4228 - Clinical Evaluation of Drug-Eluting Bead Transcatheter Arterial Chemoembolization(D-TACE) versus Conventional TACE in Treatment of unresectable Hepatocellular Carcinoma
Presenter: Yi Chen
Session: Poster Display session 1
Resources:
Abstract
3930 - Safety profile of tepotinib in patients with advanced solid tumors: pooled analysis of phase I and II data
Presenter: Thomas Decaens
Session: Poster Display session 1
Resources:
Abstract
5373 - Drug-drug interaction profile of tepotinib with CYP3A and P-gp substrates
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
5455 - Bioavailability of tepotinib: impact of omeprazole and food
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
2618 - Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2563 - Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2021 - The Addition of Metformin to Systemic Anticancer Therapy
Presenter: Jung Han Kim
Session: Poster Display session 1
Resources:
Abstract
5243 - Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
Presenter: Antoine Italiano
Session: Poster Display session 1
Resources:
Abstract
598 - Analysis of the overall survival and main surrogates used for FDA approvals in solid and hematological malignancies.
Presenter: Maria Kleniewska-Wieczor
Session: Poster Display session 1
Resources:
Abstract
5381 - Comparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): the CriTax study
Presenter: Ruben Van Eerden
Session: Poster Display session 1
Resources:
Abstract